全球心血管基因检测市场行业概况及 2031 年预测 – 市场分析和市场份额

全球心血管基因检测市场 - 行业概况

心血管基因检测有助于确定一个人患冠状动脉疾病、高血压、心肌病和其他几种与心血管系统有关的疾病的遗传风险。由于心血管疾病正在迅速渗透到全球人口中，早期识别可以让医疗专业人员更有效地制定预防措施。在这里，基因检测在评估个人患某些疾病的遗传风险方面发挥了重要作用。如果我们按照数字来算，心血管疾病每年夺走约 1790 万人的生命，是全球最大的死亡原因。心血管疾病统称为心血管疾病，包括冠心病、脑血管病和风湿性心脏病。世界卫生组织 (WHO) 进行的调查预测，到 2030 年，全球死于心血管疾病的人数将超过 2300 万。

数据桥市场研究市场报告提供了最新发展、贸易法规、市场份额、基于细分和区域分析的市场趋势、市场参与者的影响、新兴收入领域机会分析、市场法规、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地理扩展和市场技术创新的详细信息。要获取有关市场的更多信息，请联系数据桥市场研究的专家分析师团队。我们的团队将帮助您做出明智的市场决策，以实现业务增长。

全球心血管基因检测市场规模及市场分析

心血管基因检测市场也受益于检测成本的降低和可及性的扩大，同时患者和医疗保健专业人员对基因洞察的好处的认识也得到了提高。Data bridge Market Research 深入全面分析了市场，发现全球心血管基因检测市场正以 11.20% 的复合年增长率增长。2023 年市场规模为 90.7 亿美元，预计到 2031 年将增长至 190.7 亿美元。

全球心血管基因检测市场动态

全球心血管基因检测市场增长动力

心血管疾病发病率上升

为了识别出罹患此类疾病风险较高的人群，心血管基因检测变得越来越必要。及时诊断有助于在早期采取预防措施，从而遏制心力衰竭、高血压和冠状动脉疾病等心血管疾病的发病率上升。根据世界卫生组织 (WHO) 的数据，冠状动脉疾病 (CAD) 在全球范围内呈上升趋势，估计每年有 1860 万人死于心血管疾病。

提高微创技术的利用率

心血管设备行业中一个新兴细分市场是由对微创手术日益增长的需求所催生的，这些手术包括基于导管的介入和机器人辅助手术等。微创手术的进步在快速恢复、并发症风险较低和住院时间较短方面具有诸多优势，从而扩大了心血管护理应用的范围。

 健康和预防保健计划

随着预防性医疗保健的重要性日益凸显，人们越来越有兴趣了解自己的遗传风险因素，以便采取主动措施保持心血管健康。以健康和预防性医疗保健为中心的举措提高了人们对主动医疗保健价值的认识。人们开始意识到关注自己的健康并采取预防措施降低患病几率的重要性。被动医疗保健越来越不受欢迎，而预防性医疗保健则越来越受欢迎。人们正在寻找策略来尽早识别健康危害并采取预防措施来避免心血管疾病等疾病。

全球心血管基因检测市场增长机会

提高医疗保健的可及性和可负担性

Cardiovascular genetic testing market has a lot of potential because of the initiatives taken by governments and the business sector in emerging nations to lower the cost of and increase access to sophisticated healthcare. These initiatives are reaching a larger population by making the integration of genetic testing into standard medical care a priority. The need for genetic testing as a component of regular health evaluations is driven by this push for affordability and inclusivity, creating new markets for companies who deliver these technologies. Significant development opportunities exist for businesses in the cardiovascular genetic testing industry as a result of the greater accessibility and integration of genetic testing, which can improve early illness identification and individualized treatment as healthcare systems in these areas change.

Global Cardiovascular Genetic Testing Market Growth Challenges

Data Management and Interpretation

Large volumes of genetic data and complicated patterns within the intricacy of this data might be overwhelming for healthcare professionals who do not have the tools or expertise to fully understand it. This can make it more difficult for clinicians to make clinical decisions since they have to incorporate the genetic test results into patient care plans in addition to comprehending the intricacies of the results. This could make it difficult to use genetic testing effectively and efficiently in clinical practice.

Patient and Provider Acceptance

Inadequate education and awareness are a key impediment to the growth and effectiveness of the global market for cardiovascular genetic testing. Lower adoption rates may arise from healthcare providers' reluctance to propose genetic testing if they are not fully aware of how it might improve diagnosis, treatment, and prevention. Similar to this, even when recommended, patients who lack knowledge about the advantages and restrictions of genetic testing may not explore or fully utilize these choices.

Global Cardiovascular Genetic Testing Market Size Growth Restraints

Ethical and Privacy Concerns

Global Cardiovascular Genetic Testing brings up ethical concerns related to the privacy and security of personal genetic information. The handling of sensitive data, including an individual's genetic code, raises worries about how this information might be used or shared. As incidents of data breaches and misuse of personal information become more frequent, these concerns grow. Patients may be reluctant to undergo genetic testing if they are concerned about the potential exposure or misuse of their genetic data, which could discourage participation in these tests. This report on the global cardiovascular genetic testing market offers insights into recent developments, trade regulations, and import-export dynamics. It includes an analysis of production, value chain optimization, market share, and the impact of both domestic and regional players.

Expensive cost of treatment

Cardiovascular Genetic testing are expensive to conduct and require a lot of input. Testing is hence costly. Depending on the condition and test type, genetic testing costs can vary and could be very high.  Developing nations also have to deal with the issue of genetic testing being quite expensive. For example, in India, the cost of a genetic test might range higher than the standard affordable value making it an unaffordable alternative.

Global Cardiovascular Genetic Testing Market Scope and Trends

Key Insight

• Biochemical tests measure biomarkers such as troponins, which signal cardiac stress or damage, and natriuretic peptides, which indicate heart failure. These biomarkers offer additional context about the severity of cardiovascular conditions identified through genetic testing. For instance, if genetic testing detects a mutation associated with Hypertrophic Cardiomyopathy (HCM), biochemical tests can evaluate how this mutation is affecting the patient's heart function, providing a more comprehensive understanding of the disease.
• Cardiovascular Genetic testing can detect specific mutations or variations in genes linked to cardiovascular diseases, including hypertrophic cardiomyopathy, familial hypercholesterolemia, and arrhythmias. Identifying these genetic risks enables early diagnosis and intervention, allowing for timely management of these conditions.
• Incorporating cardiovascular genetic testing into routine healthcare, populations can undergo more comprehensive screening, facilitating earlier detection and treatment of cardiovascular diseases. This proactive approach enhances the management of these conditions and contributes to improved public health outcomes.
• The cardiovascular genetic testing market facilitates the development and growth of genomic databases that compile genetic variants linked to cardiovascular diseases. These databases are essential for discovering new biomarkers and enhancing the precision of molecular diagnostic tests.

Global Cardiovascular Genetic Testing Market Regional Analysis – Market Trends

Key Insights

• Europe excels in cardiovascular genetic testing market research, supported by a multitude of academic and research institutions dedicated to exploring genetic factors in cardiovascular diseases. This vibrant research ecosystem drives innovation, leading to the development of advanced genetic tests and cutting-edge technologies.
•  Despite the growth potential, the uniform adoption of cardiovascular genetic testing technologies is challenged by inconsistent reimbursement levels across countries, varying national regulations, and the necessity for healthcare professionals to receive adequate training in genetic testing.
• North America, United States and Canada, boasts a highly advanced healthcare system with sophisticated infrastructure that facilitates the integration of cardiovascular genetic testing into clinical practice.
• North America hosts premier research institutions and biotechnology firms that spearhead innovation in genetic testing. This strong focus on research and development results in the creation of state-of-the-art tests and technologies.
• APAC countries are making substantial investments in healthcare infrastructure and biotechnology, which enhances the development and implementation of cardiovascular genetic testing technologies within clinical settings.

Global Cardiovascular Genetic Testing Market Leading Players

• Bio-Rad Laboratories Inc. (U.S.)
• Danaher (U.S.)
• Daan Gene Co., Ltd. (Canada)
• F. Hoffmann-La Roche, Ltd. (Switzerland)
• Genentech, Inc. (U.S.)
• Genomictree, Inc. (South Korea)
• HTG Molecular Diagnostics, Inc. (U.S.)
• Illumina, Inc. (U.S.)
• Integragen (France)
• Laboratory Corporation of America Holdings (U.S.)
• Luminex Corporation (U.S.)
• Molecular MD Corp. (U.S.)
• Myriad Genetics, Inc. (U.S.)
• Natera, Inc. (U.S.)
• Oxford Biodynamics Plc (U.K)
• PacBio (U.S.)
• PerkinElmer Inc.（美国）
• Qiagen (德国)
• 赛默飞世尔科技公司（美国）

全球心血管基因检测市场的最新发展

• 多基因风险评分 (PRS) 的使用越来越普遍。PRS 评估各种基因变异对个人患心血管疾病风险的累积影响，从而增强风险评估并实现更加个性化的治疗策略。
• 《体外诊断法规》（IVDR）将于 2022 年 5 月生效，为体外诊断测试（包括基因测试）的审批和监督制定了更严格的标准。这些加强的标准提高了基因检测产品的准确性、可靠性和安全性，影响了其验证流程和市场准入。
• 更新后的GDPR和类似的数据保护法规要求对基因数据进行更严格的保护，确保心血管基因检测中使用的患者信息以更高的安全性进行收集、存储和处理。这些法规加强了对接受心血管基因检测的个人的隐私保护。

DBMR 的心血管基因检测市场报告将为您提供宝贵的见解，这些见解有助于您做出多项重要的业务决策。根据我们的报告和研究专业知识，您可以为您的业务制定切实可行的增长战略。    

SKU-52784